Hirudin (55-65) (sulfated)

CAS No. 109528-50-9

Hirudin (55-65) (sulfated)( ——— )

Catalog No. M39959 CAS No. 109528-50-9

Hirudin (55-65) (sulfated) is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote

Biological Information

  • Product Name
    Hirudin (55-65) (sulfated)
  • Note
    Research use only, not for human use.
  • Brief Description
    Hirudin (55-65) (sulfated) is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property.
  • Description
    Hirudin (55-65) (sulfated) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    109528-50-9
  • Formula Weight
    1491.53
  • Molecular Formula
    C64H90N12O27S
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Birnbaum S, et al. Peptide screening. Current Opinion in Biotechnology, 1992, 3(1): 49-54.
molnova catalog
related products
  • TC-O 9311

    TC-O 9311 is a potent GPR139 agonist.

  • Deferitazole

    Deferitazole (FBS 0701) is a novel and orally active, selective and high affinity iron chelator.

  • Brentuximab vedotin

    Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.